Published in Blood on October 24, 2002
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet (2010) 2.83
Adult acute lymphoblastic leukemia: concepts and strategies. Cancer (2010) 1.78
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer (2005) 1.41
Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis. Neuro Oncol (2008) 1.39
Therapeutic targeting of MLL. Blood (2009) 1.36
The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood (2005) 1.25
Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica (2010) 1.19
Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood (2011) 1.12
Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One (2011) 1.12
Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors. Haematologica (2013) 0.99
Genetic factors influencing cytarabine therapy. Pharmacogenomics (2009) 0.97
Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol (2008) 0.94
MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL. Cell Cycle (2014) 0.83
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. Nat Med (2017) 0.81
The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells. J Biol Chem (2015) 0.79
Blockade of CD82 by a monoclonal antibody potentiates anti-leukemia effects of AraC in vivo. Cancer Med (2015) 0.77
FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget (2016) 0.76
OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res (2017) 0.75
Clinical potential of elacytarabine in patients with acute myeloid leukemia. Ther Adv Hematol (2014) 0.75
MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia. Oncotarget (2016) 0.75
Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin. Leukemia (2016) 0.75
Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia. Biomed Res Int (2015) 0.75
MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. Front Pediatr (2017) 0.75
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Cell death: critical control points. Cell (2004) 22.56
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell (2002) 11.09
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell (2006) 10.29
BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science (2003) 9.55
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science (2004) 7.63
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature (2003) 6.78
Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology (2006) 6.55
A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. Dev Cell (2002) 5.45
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22
VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science (2003) 4.92
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature (2003) 4.80
Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science (2005) 4.75
Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc Natl Acad Sci U S A (2005) 4.63
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1alpha. Science (2006) 4.46
The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science (2010) 4.37
Chromatin-modifying enzymes as modulators of reprogramming. Nature (2012) 4.22
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 3.93
A stapled BID BH3 helix directly binds and activates BAX. Mol Cell (2006) 3.86
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell (2002) 3.72
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood (2008) 3.65
Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet (2007) 3.48
Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell (2003) 3.35
HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood (2008) 3.12
Apoptosis in the development and maintenance of the immune system. Nat Immunol (2003) 3.02
Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proc Natl Acad Sci U S A (2004) 3.00
Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell (2002) 2.96
Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell (2011) 2.89
Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell (2012) 2.89
In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell (2008) 2.78
Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat Med (2008) 2.78
Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis and apoptosis. EMBO J (2004) 2.77
AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell (2011) 2.77
Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc (2007) 2.71
PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 2.66
Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization. Mol Cell Biol (2003) 2.66
Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun (2003) 2.65
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood (2009) 2.57
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol (2002) 2.55
Bad-deficient mice develop diffuse large B cell lymphoma. Proc Natl Acad Sci U S A (2003) 2.54
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer (2007) 2.52
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol (2008) 2.51
Essential role of BAX,BAK in B cell homeostasis and prevention of autoimmune disease. Proc Natl Acad Sci U S A (2005) 2.43
Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci U S A (2004) 2.36
Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood (2003) 2.35
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood (2013) 2.34
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet (2011) 2.32
A role for proapoptotic BID in the DNA-damage response. Cell (2005) 2.30
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol (2012) 2.29
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res (2010) 2.22
Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes Dev (2006) 2.20
Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood (2009) 2.19
cdx4 mutants fail to specify blood progenitors and can be rescued by multiple hox genes. Nature (2003) 2.16
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood (2007) 2.12
p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science (2009) 2.11
An Mll-dependent Hox program drives hematopoietic progenitor expansion. Curr Biol (2004) 2.10
A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell (2002) 2.09
Definitive hematopoiesis requires the mixed-lineage leukemia gene. Dev Cell (2004) 2.09
Medical end-of-life decisions for children in the Netherlands. Arch Pediatr Adolesc Med (2005) 2.09
No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy. Pediatr Blood Cancer (2012) 2.08
mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell (2012) 2.06
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One (2010) 1.96
The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood (2008) 1.95
Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood (2009) 1.94
The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med (2010) 1.93
Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell (2004) 1.92
IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood (2013) 1.91
FLT3 mutations in childhood acute lymphoblastic leukemia. Blood (2003) 1.91
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat (2002) 1.91
Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol (2003) 1.86
BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol (2002) 1.84